乌司奴单抗诱导治疗溃疡性结肠炎的真实世界研究
该研究回顾性纳入法国20个GETAID中心的103例溃疡性结肠炎患者,评估乌司奴单抗诱导治疗的短期有效性和安全性。结果显示,在高度难治性人群中,第12-16周无激素临床缓解率为35.0%,临床缓解率为39.8%,不良事件发生率为7.8%。
要点
- 乌司奴单抗诱导治疗在高度难治性UC患者中第12-16周无激素临床缓解率达35.0%。
- 基线部分Mayo评分>6及既往抗TNF和维得利珠单抗双重暴露与诱导失败相关。
- 不良事件发生率7.8%,严重不良事件3.9%,短期安全性可接受。
核心结论
- 在多次既往药物失败的高度难治性UC患者中,乌司奴单抗第12-16周可使约三分之一患者达到无激素临床缓解。
- 临床严重程度及既往抗TNF和维得利珠单抗治疗史与乌司奴单抗第12-16周失败相关。
研究设计与样本
- 回顾性多中心真实世界队列研究,纳入2019年1月至9月法国20个GETAID中心的103例接受乌司奴单抗治疗的UC患者。
- 主要结局为第12-16周无激素临床缓解(部分Mayo评分≤2且直肠出血子评分≤1)。
主要发现
- 103例患者中70%既往暴露于≥2种抗TNF药物,85%既往暴露于维得利珠单抗。
- 第12-16周无激素临床缓解率为35.0%,临床缓解率为39.8%,无直肠出血且排便频率正常者占19.4%。
- 2例患者在12-16周访视前停用乌司奴单抗并接受手术。
- 多因素分析显示,基线部分Mayo评分>6与第12-16周无激素临床缓解负相关(18.6% vs 46.7%,P=0.003)。
- 既往抗TNF和维得利珠单抗双重暴露与第12-16周无激素临床缓解负相关(27.3% vs 80.0%,P=0.001)。
关键数值与推荐
- 无激素临床缓解定义为部分Mayo评分≤2且直肠出血子评分≤1。
- 基线部分Mayo评分>6者无激素临床缓解率18.6% vs 46.7%(P=0.003)。
- 既往抗TNF和维得利珠单抗双重暴露者无激素临床缓解率27.3% vs 80.0%(P=0.001)。
临床怎么用
- 对于多次生物制剂失败的难治性UC患者,乌司奴单抗诱导治疗仍可使约三分之一达到无激素临床缓解。
- 基线疾病活动度高或既往抗TNF及维得利珠单抗双重暴露者,应预期乌司奴单抗诱导应答率较低。
局限性
- 回顾性研究设计。
- 样本量有限(103例)。
- 仅评估短期(第12-16周)结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Phase III trials have demonstrated the efficacy and safety of ustekinumab in moderate-to-severe ulcerative colitis (UC), but few real-world data are currently available. AIM: To assess short-term effectiveness and safety of ustekinumab in patients with UC. METHODS: From January to September 2019, all patients with UC treated with ustekinumab in 20 French GETAID centres were retrospectively included. The primary outcome was steroid-free clinical remission (partial Mayo Clinic score ≤2) at weeks 12-16 without a rectal bleeding subscore >1. RESULTS: Among the 103 patients included, 70% had been previously exposed to ≥2 anti-TNF agents and 85% to vedolizumab. At weeks 12-16, steroid-free clinical remission and clinical remission rates were 35.0% and 39.8% respectively; the absence of rectal bleeding with normal stool frequency was noted in 19.4% of patients. Two patients discontinued ustekinumab before the week 12-16 visit and underwent surgery. In multivariable analysis, a partial Mayo Clinic score >6 at inclusion (18.6% vs 46.7%, P = 0.003) and a history of both exposure to anti-TNF and vedolizumab therapies (27.3% vs 80.0%, P = 0.001) were negatively associated with steroid-free clinical remission at weeks 12-16. Adverse events occurred in 7.8% of patients and serious adverse events in 3.9% of patients. CONCLUSION: In a cohort of highly refractory patients with UC with multiple prior drug failures, ustekinumab provided steroid-free clinical remission in one-third of cases at weeks 12-16. Clinical severity and previous use of anti-TNF and vedolizumab therapies were associated with ustekinumab failure at weeks 12-16.
引用
- Amiot A, Filippi J, Abitbol V, et al. Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort study. Aliment Pharmacol Ther. 2020. PMID: 32291786. doi:10.1111/apt.15717
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。